# A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

> **NCT06104124** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Amgen** · enrollment: 651 (actual)

## Conditions studied

- Sjogren's Syndrome

## Interventions

- **DRUG:** Dazodalibep
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06104124
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-24
- **Primary completion:** 2026-08-19
- **Final completion:** 2026-08-19
- **Target enrollment:** 651 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104124, "A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06104124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*